SRPT Q3 2021 Earnings — Sarepta Therapeutics, Inc. Revenue & Financial Results | Market Cap Arena

SRPTSarepta Therapeutics, Inc.

$2B

Q3 2021 Earnings

Healthcare Biotechnology

Income Statement

Revenue

$189M+31.6% YoY

Gross Profit

$166M87.6% margin

Operating Income

-$34M-18.2% margin

Net Income

-$48M-25.4% margin

EPS (Diluted)

$-0.60

QoQ Revenue Growth

+15.4%

Cash Flow

Operating Cash Flow

-$124M

Free Cash Flow

-$134M

Stock-Based Comp.

$27M

Balance Sheet

Total Assets

$2.7B

Total Liabilities

$2.2B

Stockholders' Equity

$470M

Cash & Equivalents

$1.6B

Year-over-Year Comparison

Metric	Current	Year Ago	Change
Revenue	$189M	$144M	+31.6%
Gross Profit	$166M	$129M	+28.7%
Operating Income	-$34M	-$137M	+74.9%
Net Income	-$48M	-$196M	+75.5%

Revenue Segments

E X O N D Y S Fifty One

$116M69%

A M O N D Y S Fourty Five

$27M16%

V Y O N D Y S Fifty Three

$25M15%